Hawaii Minority-Based Clinical Community Oncology Program

描述(由申请人提供)：夏威夷少数民族社区临床肿瘤学(MBCCOP)的主要目标是在过去15年向夏威夷癌症患者和高危个人提供国家癌症研究所(NCI)临床试验的基础上，通过以下方式减少癌症的发病率、发病率和死亡率：1.支持扩大夏威夷州的临床研究，该州是一个以少数民族患者为主的多民族人口；2.将最先进的科学治疗和预防/控制研究的优势带给自己社区的少数族裔个人；3.促进未得到充分服务的人群更广泛地参与NCI批准的研究；4.加强现有的业务基础，以扩大人口中的癌症预防和控制研究；5.增加初级保健提供者和其他专家参与癌症治疗、预防和控制研究。夏威夷癌症研究中心将作为MBCCOP的行政总部，并将指导NCI批准的癌症治疗、预防和症状控制临床试验的招募、积累和数据管理。临床试验来源包括：SWOG、GOG、COG、RTOG、URCC、CTSU和NSABP预防试验。参加会议的医生包括瓦胡岛、考艾岛、毛伊岛和夏威夷大岛的肿瘤学家以及其他医学和非医学专业的专业人员。该州的所有主要医院都将作为组成部分/附属机构。MBCCOP将允许夏威夷人(约75%为少数民族)受益于获得最先进的癌症治疗、预防和症状控制研究，同时提供关于独特人群的宝贵临床研究数据。 相关性：为夏威夷人民提供NCI批准的癌症治疗、预防和控制临床试验，特别是少数族裔和未得到充分服务的人群。降低夏威夷的癌症负担。提供关于不同种族、性别和年龄的癌症发病率、发病率、死亡率和治疗效果差异的数据。

DESCRIPTION (provided by applicant): The primary objective of the Hawaii Minority-Based Community Clinical Oncology (MBCCOP) is to build on its past 15 year success in providing National Cancer Institute (NCI) clinical trials to Hawaii cancer patients and high risk individuals in order to reduce cancer incidence, morbidity and mortality by: 1. providing support to expand clinical research in the State of Hawaii, a multiethnic population with a majority of ethnic minority patients; 2. bringing the advantages of state-of-the-science treatment and prevention/control research to minority individuals in their own communities; 3. facilitating broader participation among underserved populations in NCI-approved research; 4. strengthening the operational base that presently exists to extend cancer prevention and control research in the population; 5. increasing the involvement of primary health care providers and other specialists in cancer treatment, prevention, and control studies. The Cancer Research Center of Hawaii will serve as the administrative headquarters for the MBCCOP and will direct recruitment, accrual, and data management for NCI-approved cancer treatment, prevention and symptom control clinical trials. Sources of clinical trials include: SWOG, GOG, COG, RTOG, URCC, CTSU, and NSABP prevention trials. Participating physicians include oncologists on Oahu, Kauai, Maui, and the Big Island of Hawaii as well as professionals from other medical and non-medical specialties. All major hospitals in the state will serve as component/affiliate institutions. The MBCCOP will allow the people of Hawaii, about 75% who are ethnic minorities, to benefit from access to state-of-the-science cancer treatment, prevention and symptom control studies while providing valuable clinical research data on a unique population. RELEVANCE: Provide access to NCI-approved cancer treatment, prevention and control clinical trials for the people of Hawaii especially for minorities and under-served populations. Lower the burden of cancer in the State of Hawaii. Provide data on differences in cancer incidence, morbidity, mortality and treatment effects as a function of ethnicity, gender, and age.